Cardiovascular Diseases


Antiplatelets and Beta-Blockers Linked to Heat-Related Heart Attacks

Data from a validated and complete registration of all 2,494 acute myocardial infarction (MI) cases in Augsburg, Germany, during warm seasons (May to September) from 2001 to 2014, suggested that heat-related non-fatal MI risk was elevated among users of anti-platelet medication and beta-receptor blockers, respectively, but not among non-users, with […]


Life’s Essential 8

The American Heart Association has updated a construct of cardiovascular health (CVH), Life’s Essential 8, including diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, and blood pressure. Each metric has a new scoring algorithm ranging from 0 to 100 points, allowing generation of a […]


Dose‐Response of Omega‐3 Fatty Acids for Lowering BP

A dose‐response meta‐analysis suggested that the optimal combined intake of omega‐3 fatty acids for blood pressure (BP) lowering is likely between 2 g/d and 3 g/d. Doses above 3 g/d may be associated with additional benefits in lowering BP among high risk groups for cardiovascular diseases. The analysis included 71 randomized controlled trials […]


Very High HDL-C Linked to Higher Mortality

A prospective, multicenter biobank cohort study in the UK and US revealed that very high high-density lipoprotein cholesterol (HDL-C) levels were associated with higher mortality risk in patients with coronary artery disease (CAD). There were 14 478 UK participants (from 2006; mean age 62.1 years, 76.2% men) and 5467 US participants […]


Prevalence and Clinical Significance of DNA Variants Predisposing to Cardiomyopathy

A genetic association study indicates that 0.7% of participants harbor a pathogenic variant related to inherited cardiomyopathy and are at increased risk of cardiovascular disease (CVD) and all-cause mortality. The study included 9667 US participants (mean age 54.0 years; 43.8% women; 27.5% African and 72.5% European ancestry) and 49 744 UK […]


SGLT2 Inhibitor’s Heart Benefit Extended

A systematic review and meta-analysis concluded that sodium–glucose cotransporter-2 (SGLT2) inhibitors reduced hospitalizations for heart failure (HF) regardless of the presence of diabetes. The analysis included trials that randomly assigned adults with HF to SGLT2 inhibitors or control. Time-to-event individual patient data were reconstructed from published Kaplan–Meier plots; time-varying risk […]